USFDA approves Danish drugmaker Lundbeck's migraine prevention therapy

As Lundbeck enters the crowded market, it hopes to carve a niche for itself through its dosing frequency

The US Food and Drug Administration approved Lundbeck A/S’ migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.

For Lundbeck, the approval opens doors to a lucrative but competitive market dominated by already approved rivals from Amgen, Teva Pharmaceutical Industries and Eli Lilly and Co.

Lundbeck’s Vyepti belongs to a class of drugs called monoclonal antibodies (mAb) that are laboratory-produced molecules engineered to serve as substitute disease-fighting antibodies. Vyepti, also known as eptinezumab, inhibits calcitonin gene-related peptide (CGRP), which plays a key role in causing migraine pain.

Eptinezumab